Traffic of antibody-secreting cells after immunization with a liposome-associated, CpG-ODN-adjuvanted oral cholera vaccine.
An oral cholera vaccine made up of heat-treated recombinant cholera toxin (rCT), V. cholerae lipopolysaccharide (LPS), and recombinant toxin-co-regulated pili subunit A (rTcpA), entrapped in liposomes in the presence of unmethylated bacterial CpG-DNA (ODN#1826) was used to orally immunize a group of eight week old rats. A booster dose was given 14 days later. Control rats received placebo (vaccine diluent). The kinetics of the immune response were investigated by enumerating the antigen specific-antibody secreting cells (ASC) in the blood circulation and intestinal lamina propria using the ELISPOT assay and a histo-immunofluorescence assay (IFA), respectively. ASC of all antigenic specificities were detected in the blood of the vaccinated rats as early as two days after the booster dose. The numbers of LPS-ASC and TcpA-ASC in the blood were at their peak at day 3 post booster while the number of CT-ASC was highest at day 4 after the booster immunization. At day 13 post immunization, no ASC were detected in the blood. A several fold increase in the number of ASC of all antigenic specificities in the lamina propria above the background numbers of the control animals were found in all vaccinated rats at days 6 and 13 post booster (earlier and later time points were not studied). Vibriocidal antibody and specific antibodies to CT, LPS and TcpA were detected in 57.1% and 52.4%, 14.3%, and 19.0% of the orally vaccinated rats, respectively. The data indicated that rats orally primed with the vaccine could produce a rapid anamnestic response after re-exposure to the V. cholerae antigens. Thus, a single dose of the vaccine is expected to elicit a similar anamnestic immune response in people from cholera endemic areas who have been naturally primed to V. cholerae antigens, while two doses at a 14 day interval should be adequate for a traveler to a disease endemicarea.
Somroop
Srinuan
S
Faculty of Allied Health Sciences, Thammasat University, Rangsit Center, Pathumthani, Thailand.
Tongtawe
Pongsri
P
Chaisri
Urai
U
Tapchaisri
Pramuan
P
Chongsa-nguan
Manas
M
Srimanote
Potjanee
P
Chaicumpa
Wanpen
W
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D000921:Antibody-Producing Cells / Q000166:cytology / Q000276:immunology*; D000942:Antigens, Bacterial; D002465:Cell Movement / Q000187:drug effects* / Q000276:immunology; D022121:Cholera Vaccines / Q000276:immunology / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D007117:Immunization, Secondary; D007156:Immunologic Memory / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000166:cytology / Q000276:immunology; D008081:Liposomes; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000276:immunology / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; C408982:CPG-oligonucleotide; D022121:Cholera Vaccines; D008081:Liposomes; D009838:Oligodeoxyribonucleotides; D014614:Vaccines, Synthetic